Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients

NCT04414540 is registered in ClinicalTrials.gov with Trisha Wise-Draper as lead sponsor.

NCT NCT04414540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04414540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients
Lead sponsor
Trisha Wise-Draper
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 31, 2020
Completion date
September 30, 2026
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma